National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Ministry of Chemicals and Fertilizer, Opposite Air Force Station, Gandhinagar 382355, Gujarat, India.
National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Ministry of Chemicals and Fertilizer, Opposite Air Force Station, Gandhinagar 382355, Gujarat, India.
J Control Release. 2021 Feb 10;330:372-397. doi: 10.1016/j.jconrel.2020.12.034. Epub 2020 Dec 25.
Nanomedicines refers to nanotechnology inspired pharmaceutical products often referred to as 'nanopharmaceuticals.' It has displayed commendable potential in enhancing therapeutic efficacy as well as in reducing the side effects associated with conventional drug counterpart. Recent years have monitored the entry of a large amount of nanomedicine in the market with an appreciable market share to date. Despite this, the development of nanomedicine is posing challenges (i.e., safety, regulatory hurdles, cost, scale-up issues, etc.) that need to be resolved for their market entry. This review presents a cross-sectional discussion on the nanomedicine-derived products available in the market for both clinical and diagnostic applications. An overview of its market potential, market size, and the products that are currently in the clinical stages is also provided. The review also expounds on the challenges faced by nano-drug products at the time of their commercialization.
纳米医药是指受纳米技术启发的药物产品,通常被称为“纳米药物”。它在提高治疗效果和降低传统药物副作用方面表现出了令人瞩目的潜力。近年来,大量的纳米医药产品已经进入市场,并占据了可观的市场份额。尽管如此,纳米医药的发展仍面临着一些挑战(如安全性、监管障碍、成本、规模化问题等),这些挑战需要得到解决,才能使其进入市场。本综述对可用于临床和诊断应用的市场上现有的纳米医药产品进行了跨学科讨论。概述了其市场潜力、市场规模以及处于临床阶段的产品。本文还阐述了纳米药物产品在商业化过程中所面临的挑战。